Orphan medicine, Ramucirumab (Cyramza®), provides long-awaited advance for difficult to treat stomach cancer
First approved therapy specifically indicated for second-line advanced stomach and gastro-oesophageal junction cancer receives marketing authorisation in Europe
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Marketing